Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Carmen Black Parker, MD, Amanda Calhoun, MD, MPH, Ambrose H. Wong, MD, MSEd, Larry Davidson, PhD, and Charles Dike, MBChB, MPH
Psychiatric emergencies, coping stress reactions, and iatrogenic injuries are not responded to with the same vigor as acute medical decompensation. That needs to change.
AMA J Ethics. 2020;22(11):E956-964. doi:
10.1001/amajethics.2020.956.
Deborah M. Eng, MS, MA and Scott J. Schweikart, JD, MBE
A just culture perspective suggests that punitive responses to those who err should be reserved for those who have willfully and irremediably caused harm.
AMA J Ethics. 2020;22(9):E779-783. doi:
10.1001/amajethics.2020.779.
Sarah Reinhardt, MPH, RD and Ricardo J. Salvador, PhD, MS
Clinicians should contribute to healthful, equitable, sustainable food procurement initiatives consistent with their institutions' health-promotion missions.
AMA J Ethics. 2018;20(10):E974-978. doi:
10.1001/amajethics.2018.974.